Niraparib vs stenoparib

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Ovarian Cancer

Shared mechanism: PARP1/2 · full Ovarian Cancer pipeline

Niraparib

Marketed by GlaxoSmithKline and partners

Approved in Ovarian Cancersmall molecule
Reliable signal

NCT02655016 · Phase 3 · active, not recruiting

Patients were randomly assigned to niraparib or a matching placebo, with patients, doctors and outcome assessors all blinded. Progression-free survival, read by a blinded independent central review, was significantly longer with niraparib (hazard ratio 0.62, p<0.0001). The protocol reports a power calculation for this endpoint and 733 patients were enrolled against a planned 620.

Next expected readout: December 2026 · NCT05335993 (registry estimate)

Reported efficacy

Progression Free Survival (Up to 34 months): Progression Free Survival (Up to 34 months): Placebo 8.2 Months (95% CI 7.3 to 8.5) | Niraparib 13.8 Months (95% CI 11.5 to 14.9) (met)

Result source: NCT02655016

stenoparib

Developed by Allarity Therapeutics, Inc. under a licence from Eisai

Phase 2 in Ovarian Cancersmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: March 2027 · NCT03878849 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Ovarian Cancer

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

stenoparib: no structured comparison results are available for Ovarian Cancer.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Niraparib

ORR 15.1% (n=53) @ 40wk
responder rate · % of participants
No placebo or comparator arm
NCT02657889 · Phase 1/2 · registry result, not featured evidence · combination
show 1 more result
18.2% (n=55) @ 40wk
NCT02657889 · Phase 1/2 · registry result, not featured evidence · combination
Duration of Response 14.4 months
time to event · months
No placebo or comparator arm
NCT02657889 · Phase 1/2 · registry result, not featured evidence · combination
show 1 more result
21.5 months
NCT02657889 · Phase 1/2 · registry result, not featured evidence · combination
Disease Control 58.5% (n=53) @ 40wk
responder rate · % of participants
No placebo or comparator arm
NCT02657889 · Phase 1/2 · registry result, not featured evidence · combination
show 1 more result
41.8% (n=55) @ 40wk
NCT02657889 · Phase 1/2 · registry result, not featured evidence · combination
PFS 3.4 months
time to event · months
No placebo or comparator arm
NCT02657889 · Phase 1/2 · registry result, not featured evidence · combination
show 1 more result
2.5 months
NCT02657889 · Phase 1/2 · registry result, not featured evidence · combination
Overall Survival 17.1 months
time to event · months
No placebo or comparator arm
NCT02657889 · Phase 1/2 · registry result, not featured evidence · combination
show 1 more result
9.4 months
NCT02657889 · Phase 1/2 · registry result, not featured evidence · combination
Available safety results

Niraparib

Dropout rate
n/a: no completion milestonePhase 1: Niraparib 300 mg + Pembro
NCT02657889 · Phase 1/2 · registry result, not featured evidence · combination
show 5 more results
n/a: no completion milestonePhase 1: Niraparib 200 mg + Pembro
NCT02657889 · Phase 1/2 · registry result, not featured evidence · combination
—Phase 2 OC: Niraparib 200 mg + Pem
NCT02657889 · Phase 1/2 · registry result, not featured evidence · combination
—Phase 2 OC: Niraparib 200mg + Pemb
NCT02657889 · Phase 1/2 · registry result, not featured evidence · combination
—Phase 2 TNBC: Niraparib 200 mg + P
NCT02657889 · Phase 1/2 · registry result, not featured evidence · combination
—Phase 2 TNBC: Niraparib 200mg + Pe
NCT02657889 · Phase 1/2 · registry result, not featured evidence · combination
Discontinued due to AEs
—Phase 1: Niraparib 300 mg + Pembro
NCT02657889 · Phase 1/2 · registry result, not featured evidence · combination
show 5 more results
—Phase 1: Niraparib 200 mg + Pembro
NCT02657889 · Phase 1/2 · registry result, not featured evidence · combination
—Phase 2 OC: Niraparib 200 mg + Pem
NCT02657889 · Phase 1/2 · registry result, not featured evidence · combination
—Phase 2 OC: Niraparib 200mg + Pemb
NCT02657889 · Phase 1/2 · registry result, not featured evidence · combination
—Phase 2 TNBC: Niraparib 200 mg + P
NCT02657889 · Phase 1/2 · registry result, not featured evidence · combination
—Phase 2 TNBC: Niraparib 200mg + Pe
NCT02657889 · Phase 1/2 · registry result, not featured evidence · combination
Serious AEs
57.1%Phase 1: Niraparib 300 mg + Pembro
NCT02657889 · Phase 1/2 · registry result, not featured evidence · combination
show 5 more results
85.7%Phase 1: Niraparib 200 mg + Pembro
NCT02657889 · Phase 1/2 · registry result, not featured evidence · combination
41.5%Phase 2 OC: Niraparib 200 mg + Pem
NCT02657889 · Phase 1/2 · registry result, not featured evidence · combination
—Phase 2 OC: Niraparib 200mg + Pemb
NCT02657889 · Phase 1/2 · registry result, not featured evidence · combination
43.6%Phase 2 TNBC: Niraparib 200 mg + P
NCT02657889 · Phase 1/2 · registry result, not featured evidence · combination
—Phase 2 TNBC: Niraparib 200mg + Pe
NCT02657889 · Phase 1/2 · registry result, not featured evidence · combination
Most frequent reported AEs
anaemia 71.4%
dyspnoea 57.1%
nausea 57.1%
NCT02657889 · Phase 1/2 · registry result, not featured evidence · combination
show 3 more results
anaemia 71.4%
constipation 71.4%
fatigue 57.1%
NCT02657889 · Phase 1/2 · registry result, not featured evidence · combination
fatigue 60.4%
nausea 60.4%
constipation 52.8%
NCT02657889 · Phase 1/2 · registry result, not featured evidence · combination
nausea 61.8%
fatigue 54.5%
anaemia 43.6%
NCT02657889 · Phase 1/2 · registry result, not featured evidence · combination

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Niraparib's landscape · stenoparib's landscape